Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emfilermin for Recurrent Implantation Failure
NCT00504608Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Apr 2003
- Primary completion
- Apr 2004
- Modality
- Hormones & Growth Factors
01
Overview
A Phase 2 trial of emfilermin in Recurrent Implantation Failure (RIF), sponsored by Merck KGaA. Started Apr 2003; status: completed.
02
Drugs
emfilermin
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT00504608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504608.